Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

Phase 2positivemosliciguatPositive

AI Analysis

Summary

Roivant announced positive Phase 2 PHocus trial results for mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, with an ongoing Phase 3 PHrontier study underway.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Positive results from Phase 2 PHocus trial

Importance:7/10

Sentiment:

0.80

Phase 2 datapulmonary hypertensioninterstitial lung diseasepositive resultsclinical trial

Related Companies

$ROIV

Read the original article

Published by GlobeNewswire Pharma on September 8, 2026 10:00 AM

Read Original